

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**Form PTO-1449 (Modified)
Use several sheets if necessary)

Sheet 1 of 1

COMPLETE IF KNOWN

Application Number	10/567,470
Confirmation Number	4986
Filing Date	November 30, 2006
First Named Inventor	Iversen <i>et al.</i>
Group Art Unit	1635
Examiner Name	Angell, Jon E.
Attorney Docket No.	50450-8055.US00

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent or Application		Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		NUMBER	Kind Code (if known)			
	1.	US-5,194,428		Agrawal <i>et al.</i>	03-16-1993	
	2.	US-5,801,154		Baracchini <i>et al.</i>	09-01-1998	
	3.	US-5,892,023		Pirotzky <i>et al.</i>	04-06-1999	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent or Application			Name of Patentee or Applicant of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	NUMBER	Kind Code (if known)				
	4.	PCT	WO 06/047683	A2	AVI Biopharma, Inc.	04-05-2006		

OTHER NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
	5.	Agrawal <i>et al.</i> "Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus", <i>Proc Natl Acad Sci U S A.</i> , 85(19):7079-7083 (1988).	
	6.	Basler <i>et al.</i> , "The Ebola virus VP35 protein functions as a type I IFN antagonist", <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 97(22):12289-12294 (2000).	
	7.	Copy of the International Search Report and Written Opinion for PCT/US2007/011435, search report dated, September 29, 2008, 10 pages (2008).	
	8.	Crooke, S. T., <i>Antisense Drug Technology: Principles, Strategies, and Applications</i> . New York, Marcel Dekker, S. Crooke Ed Springer Pages 1-50 (1999).	
	9.	Jen <i>et al.</i> , "Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies", <i>Stem Cells</i> , 18:307-319 (2000).	
	10.	Scanlon, K.I., "Anti-genes: siRNA, ribozymes and antisense", <i>Current Pharmaceutical Biotechnology</i> , 5(5):415-420 (2004).	
	11.	Taylor <i>et al.</i> , "Antisense oligonucleotides: a systematic high-throughput approach to target validation and gene function determination", <i>Drug Discovery Today</i> , 4:562-567 (1999).	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).